Multiresistant Bacterial Pathogens Causing Bacterial Pneumonia and Analyses of Potential Risk Factors from Northeast Ethiopia

Table 3

Antimicrobial resistance profile of bacterial isolates, Dessie, 2020.

GP isolates	Antimicrobials tested
	E	OXA	TE	COT	DA	CN	P	CXT	C	CIP
S. pneumoniae (n = 39)	19 (48.7)	22 (56.4)	16 (41.0)	5 (12.8)	4 (10.3)	NT	NT	NT	NT	NT
S. aureus (n = 29)	14 (48.3)	NT	25 (86.2)	21 (72.4)	3 (10.3)	8 (27.6)	22 (75.9)	10 (34.5)	8 (27.6)	7 (24.)
GN isolates	AMP	AMC	TZP	CRO	AK	CXM	CIP	COT	CN	IMP	GAZ	TE	c	PEP	MER	AZT
K. pneumoniae (n = 44)	44 (100)	39 (88.6)	2 (4.5)	6 (13.6)	4 (9.1)	2 (4.5)	1 (2.3)	39 (88.6)	7 (15.9)	6 (13.6)	3 (6.8)	42 (95.5)	35 (79.5)	NT	NT	NT
P. aeruginosa (n = 22)	NT	NT	2(9.1)	NT	2 (9.1)	NT	1 (4.5)	NT	12 (54.5)	1 (4.5)	14 (63.6)	NT	NT	2 (9.1)	NT	NT
H. influenzae (n = 11)	6 (54.5)	0 (0)	NT	4 (36.4)	NT	NT	4 (36.4)	NT	NT	NT	NT	10 (90.9)	NT	NT	0 (0)	0 (0)
E. coli (n = 7)	5 (71.4)	3 (42.9)	1 (14.3)	1 (14.3)	1 (14.3)	1 (14.3)	0 (0)	5 (71.4)	1 (14.3)	1 (14.3)	1 (14.3)	5 (71.4)	5 (71.4)	NT	NT	NT
A. baumannii (n = 3)	NT	NT	2 (66.7)	NT	1 (33.3)	NT	2 (66.7)	2 (66.7)	2 (66.7)	NT	2 (66.7)	2 (66.7)	NT	2 (66.7)	1 (33.3)	NT
K. oxytoca (n = 2)	2 (100)	1 (50)	0 (0)	0 (0)	0 (0)	1 (50)	0 (0)	1 (50)	0 (0)	0 (0)	0 (0)	2 (50)	2 (100)	NT	NT	NT

Note: GP, Gram-positive; GN, Gram-negative; E, erythromycin; OXA, oxacillin; DA, clindamycin; P, penicillin; CXT, cefoxitin; AMP, ampicillin; AMC, amoxicillin/clavulanate; TZP, piperacillin/tazobactam; CRO, ceftriaxone; AK, amikacin; CXM, cefuroxime; CIP, ciprofloxacin; COT, co-trimoxazole; CN, gentamicin; IMP, imipenem; CAZ, ceftazidime; TE, tetracycline; C, chloramphenicol; PEP, cefepime; MER, meropenem; AZT, aztreonam; NT, not tested (based on CLSI-2019 Guideline).